Most isolates of Staphylococcus aureus produce a serotype 5 (CP5) or 8 (CP8) capsular
polysaccharide. To investigate whether CP5 and CP8 differ in their biological properties, we …

Most clinical Staphylococcus aureus strains produce either type 5 or type 8 capsular
polysaccharides. The production of these capsules is influenced by various environmental …

This chapter focuses on major advances in staphylococcal capsule research. The cap5 and
cap8 genes required for the synthesis of CP5 and CP8, respectively, have been cloned and …

Staphylococcus aureus is a major cause of nosocomial and community-acquired infections.
The predominance of two capsular polysaccharides, types 5 and 8, on the surface of clinical …

This study addresses the regulation of Staphylococcus aureus type 8 capsular
polysaccharide (CP8) expression by the global regulators agr and sarA. We analyzed CP8 …

Most clinical isolates of Staphylococcus aureus produce microcapsules (uronic acid-
containing extracellular polysaccharides) that are detectable by serologic methods but are …

The surface capsular polysaccharide (CP) is a virulence factor that has been used as an
antigen in several successful vaccines against bacterial pathogens. A vaccine has not yet …

Type 8 capsular polysaccharide (CP8) is widely prevalent among clinical isolates of
Staphylococcus aureus, but the role that the capsule plays in the pathogenesis of …

Serotype 5 and 8 capsular polysaccharides predominate among clinical isolates of
Staphylococcus aureus. The results of experiments in animal models of infection have …

The serotype 5 capsule gene cluster of Staphylococcus aureus comprises 16 genes (cap5A
through cap5P), but little is known about how the putative gene products function in capsule …